• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载脂蛋白 L3 基因 rs738409 多态性与肝硬化患者肝细胞癌发生及风险预测模型的建立

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

机构信息

University Paris 13-UFR SMBH/INSERM U698, Bobigny, France.

出版信息

J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.

DOI:10.1016/j.jhep.2012.09.036
PMID:23069476
Abstract

BACKGROUND & AIMS: Several studies have reported an association between the genetic variant rs738409 (G) in the PNPLA3 gene and the risk of cirrhosis in various liver diseases. Our purpose was to assess the influence of this polymorphism on the risk of hepatocellular carcinoma (HCC) occurrence in two distinct longitudinal cohorts of patients with cirrhosis as well as its possible usefulness in HCC-risk model prediction.

METHODS

PNPLA3 rs738409 genotypes were assessed in 279 patients with alcoholic- and 253 patients with HCV-related cirrhosis. These patients were followed-up and screened for the risk of HCC, and the influence of rs738409 on the occurrence of liver cancer was assessed using the Kaplan-Meier method, then according to the multivariate Cox model.

RESULTS

In patients with HCV-related cirrhosis, rs738409 genotypes did not influence the risk of HCC development (log-rank = 0.7) or death (log-rank = 0.2). Conversely, in patients with alcoholic cirrhosis, the rs738409 (GG) genotype was an independent risk factor for HCC occurrence (HR = 1.72 [1.21-2.45], log-rank = 0.002) as well as older age, male gender, and higher BMI. Combining these features enabled HCC-risk stratification of this population into three groups with the 6-year cumulative incidence ranging from 3.4% (low risk, n = 58), 12.2% (intermediate risk, n = 163), and 51.7% (high risk, n = 58), respectively (HR = 4.3 [2.7-6.4]; log-rank <0.0001).

CONCLUSIONS

This study provides key data that affirm the influence of the rs738409 (GG) genotype on the occurrence of HCC in patients with alcoholic cirrhosis. Its combination with clinical features refines the selection of patients at higher risk of liver cancer development.

摘要

背景与目的

几项研究报告称,PNPLA3 基因中的遗传变异 rs738409(G)与各种肝病中的肝硬化风险之间存在关联。我们的目的是评估该多态性对两个不同的肝硬化患者纵向队列中肝细胞癌(HCC)发生风险的影响,以及其在 HCC 风险模型预测中的可能用途。

方法

在 279 例酒精性和 253 例 HCV 相关肝硬化患者中评估了 PNPLA3 rs738409 基因型。对这些患者进行了随访和 HCC 风险筛查,并使用 Kaplan-Meier 方法评估 rs738409 对肝癌发生的影响,然后根据多变量 Cox 模型进行评估。

结果

在 HCV 相关肝硬化患者中,rs738409 基因型不影响 HCC 发展的风险(对数秩=0.7)或死亡风险(对数秩=0.2)。相反,在酒精性肝硬化患者中,rs738409(GG)基因型是 HCC 发生的独立危险因素(HR=1.72[1.21-2.45],对数秩=0.002),以及年龄较大、男性和更高的 BMI。将这些特征结合起来,可以将该人群的 HCC 风险分层为三组,6 年累积发生率分别为 3.4%(低危,n=58)、12.2%(中危,n=163)和 51.7%(高危,n=58)(HR=4.3[2.7-6.4];对数秩<0.0001)。

结论

本研究提供了关键数据,证实了 rs738409(GG)基因型对酒精性肝硬化患者 HCC 发生的影响。其与临床特征的结合可细化选择发生肝癌风险较高的患者。

相似文献

1
PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.载脂蛋白 L3 基因 rs738409 多态性与肝硬化患者肝细胞癌发生及风险预测模型的建立
J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.
2
Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.载脂蛋白基因 3(rs738409 C>G)变体与亚洲慢性丙型肝炎患者肝细胞癌的关系:一项纵向研究。
J Formos Med Assoc. 2018 Sep;117(9):833-840. doi: 10.1016/j.jfma.2017.10.003. Epub 2017 Oct 28.
3
PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.载脂蛋白基因 PNPLA3 rs738409C/G 多态性与肝硬化:与肝病病因及肝细胞癌发生的关系。
Liver Int. 2011 Sep;31(8):1137-43. doi: 10.1111/j.1478-3231.2011.02534.x. Epub 2011 Apr 19.
4
Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.趋化因子 RANTES 启动子二态性与酒精性或丙型肝炎病毒相关肝硬化患者肝细胞癌的发生。
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1439-46. doi: 10.1158/1055-9965.EPI-11-0341. Epub 2011 May 24.
5
Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.酒精性或病毒性丙型肝硬化患者肝细胞癌的危险因素。
Clin Gastroenterol Hepatol. 2006 Aug;4(8):1062-8. doi: 10.1016/j.cgh.2006.05.013. Epub 2006 Jul 14.
6
The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis.载脂蛋白 L3(PNPLA3)rs738409 148M/M 基因型是酒精性肝硬化肝癌的危险因素,但在丙型肝炎肝硬化中无关联或关联较弱。
PLoS One. 2011;6(11):e27087. doi: 10.1371/journal.pone.0027087. Epub 2011 Nov 7.
7
PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals.载脂蛋白 L3 基因 I148M(rs738409) 遗传变异与肥胖个体的肝细胞癌有关。
Dig Liver Dis. 2012 Dec;44(12):1037-41. doi: 10.1016/j.dld.2012.05.006. Epub 2012 Jun 15.
8
The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients.脂肪营养蛋白I148M变体是北非患者丙型肝炎病毒相关肝癌的一个风险因素。
Infect Genet Evol. 2014 Jan;21:179-83. doi: 10.1016/j.meegid.2013.11.005. Epub 2013 Nov 20.
9
A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.载脂蛋白 PLA3 基因变异与丙型肝炎病毒感染者肝纤维化进展相关,但与肝细胞癌无关。
Clin Gastroenterol Hepatol. 2016 Feb;14(2):295-300. doi: 10.1016/j.cgh.2015.08.018. Epub 2015 Aug 21.
10
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.PNPLA3基因rs738409位点和TM6SF2基因rs58542926位点的变异增加了酒精性肝硬化患者患肝细胞癌的风险。
Dig Liver Dis. 2016 Jan;48(1):69-75. doi: 10.1016/j.dld.2015.09.009. Epub 2015 Sep 28.

引用本文的文献

1
Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes.荟萃分析:脂肪性肝病相关基因风险等位基因对纵向结局的影响。
Aliment Pharmacol Ther. 2025 Aug;62(3):244-276. doi: 10.1111/apt.70256. Epub 2025 Jun 28.
2
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application.非酒精性脂肪性肝炎相关肝病(MASLD)遗传学的最新进展:对疾病机制的见解及临床应用的新前沿
Hepatol Commun. 2025 Jan 7;9(1). doi: 10.1097/HC9.0000000000000618. eCollection 2025 Jan 1.
3
Integrating PNPLA3 into clinical risk prediction.
将PNPLA3纳入临床风险预测。
Liver Int. 2025 Mar;45(3):e16103. doi: 10.1111/liv.16103. Epub 2024 Sep 16.
4
Lactylation signature identifies liver fibrosis phenotypes and traces fibrotic progression to hepatocellular carcinoma.乳糖化特征可识别肝纤维化表型,并追踪纤维化向肝细胞癌的进展。
Front Immunol. 2024 Aug 27;15:1433393. doi: 10.3389/fimmu.2024.1433393. eCollection 2024.
5
Genetics of liver disease in adults.成人肝脏疾病的遗传学。
Hepatol Commun. 2024 Mar 29;8(4). doi: 10.1097/HC9.0000000000000408. eCollection 2024 Apr 1.
6
Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.探索酒精使用障碍和酒精性肝病易感性及发病机制的基因组学方法。
Hepatology. 2025 May 1;81(5):1595-1606. doi: 10.1097/HEP.0000000000000617. Epub 2023 Oct 2.
7
Advances and Controversies in Acute Alcohol-Related Hepatitis: From Medical Therapy to Liver Transplantation.急性酒精性肝炎的进展与争议:从药物治疗到肝移植
Life (Basel). 2023 Aug 24;13(9):1802. doi: 10.3390/life13091802.
8
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis.全球酒精相关性肝病的患病率、发病率和结局:系统评价和荟萃分析。
BMC Public Health. 2023 May 11;23(1):859. doi: 10.1186/s12889-023-15749-x.
9
The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective.慢性肝病在肝细胞癌发生和复发中的作用:组学视角
Front Med (Lausanne). 2022 Jun 24;9:888850. doi: 10.3389/fmed.2022.888850. eCollection 2022.
10
Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations.生活方式与肝细胞癌:证据与预防建议
Cancers (Basel). 2021 Dec 26;14(1):103. doi: 10.3390/cancers14010103.